Brian J Caveney Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 day, 6 hours ago
Brian J Caveney has an estimated net worth of at least $10.2 million*, as of yesterday. They own 36,491 shares of LH stock. They have sold 3,500 shares of LH stock since 2021, for an estimated $903,032.
Brian J Caveney $LH SEC Form 4 Insider Trading
Brian J Caveney has filed a total of 4 insider trades in $LH since 2021. Their most recent trade was a sale of 1,500 shares, made on Feb 24, 2026. Their largest trade was a sale of 2,000 shares, made on Jun 03, 2025. We estimate that they now own 36,491 shares of $LH, worth an estimated $9.3 million.
Insider Trading at $LH
There have been a total of 110 insider trades reported at $LH since 2021, with 3,586 shares purchased and 298,986 shares sold. The most active insider traders in $LH stock have been Der Vaart Sandra D Van, Glenn A Eisenberg, and Peter J Wilkinson. The most recent trade was a sale of 1,633 shares reported by Peter J Wilkinson (SVP, Chief Accounting Officer), made on Mar 27, 2026.
History of Insider Stock Trades by Brian J Caveney
$LH Executives and Stock Owners with Insider Trades
-
Der Vaart Sandra D Van, EVP, Chief Legal Officer
-
Glenn A Eisenberg, Chief Financial Officer, EVP
-
Peter J Wilkinson, SVP, Chief Accounting Officer
-
Mark S Schroeder, EVP, President-Diagnostics Lab
-
Adam H Schechter, President & CEO
-
Amy B. Summy, EVP, Chief Marketing Officer
-
Mark S Schroeder, EVP, Pres Diagnostics & COO
-
Jonathan C Meltzer, EVP, Operations
-
Brian J Caveney, EVP, Pres of ED, CMO & CSO
-
Brian J Caveney, EVP, President of Diagnostics
-
Lance Berberian, EVP, CIO & CTO
-
Paul R Kirchgraber, CEO, Covance Drug Development
-
Glenn A Eisenberg, Executive Vice President
-
Jonathan P. Divincenzo, EVP, Pres, Central Labs & Intl
-
Der Vaart Sandra D Van, EVP, Corporate Affairs
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.